Scope of the Study
A protein kinase inhibitor refers to the type of enzyme inhibitor which blocks the action of one or more protein kinases and considered as a potential help for preventing the growth of cancerous cells. The increasing number of cancer patients driving the demand for novel treatment. According to the World Health Organization (WHO), cancer led to 9.6 million deaths in 2018 globally. Further, growing healthcare infrastructure in the developing economies and emphasizing on advanced treatment for cancer expected to drive the demand for kinase inhibitors over the forecasted period.
The market study is being classified by Type (Tyrosin Kinase Inhibitors (TKI), Receptor Tyrosine Kinase Inhibitors, Non-Receptor Tyrosine Kinase Inhibitors, Mulikinase Inhibitors, Threonine Kinase Inhibitor, RHO Kinase Inhibitors, Cyclin Dependant Kinase Inhibitor, Aurora Kinase Inhibitors, MAP/MEK Kinase Inhibitors and Others), by Application (Lung Cancer, Breast Cancer, Renal Cell Cancer and Others) and major geographies with country level break-up.
Roche Holding AG (Switzerland), Novartis (Switzerland), AstraZeneca (United Kingdom), Bayer (Germany), Pfizer (United States), GlaxoSmithKline (United Kingdom), Bristol-Myers Squibb (United States), Cytrx Corporation (United States), Eisai Inc. (United States) and Merck Serono SA (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Eton Bioscience Inc. (United States) and Inhibikase Therapeutics, Inc. (United States).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Kinase Inhibitors market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Kinase Inhibitors market by Type, Application and Region.
On the basis of geography, the market of Kinase Inhibitors has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Pharmaceutical companies will boost the Kinase Inhibitors market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Number of Cancer Patients
- Rising Applications of Kinase Inhibitors in Cancer Therapies
- Rising Adoption of Advanced Technologies for Cancer Treatment
- Technological Advancement in the Healthcare Industry
- Stringent Government Regulations Regarding Approval Procedure
- High Cost of Cancer Treatment
- Rise in Number of Clinical Trials
- Increasing Demand from the Developing Economies
- Lack of Advanced Healthcare Infrastructure in the Low and Middle Income Group Countries
“The US FDA has approved 48 small molecule protein kinase inhibitors, nearly all of which are orally effective with the exceptions of netarsudil (which is given as an eye drop) and temsirolimus (which is given intravenously). Of the 48 approved drugs, the majority (25) target receptor protein-tyrosine kinases, ten target non-receptor protein-tyrosine kinases, and 13 target protein-serine/threonine protein kinases.”
Key Target AudienceResearch Organizations, Potential Investors, Government Regulatory Authorities, Research and Development Companies and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase